RCPT 109.24 Receptos Inc $RCPT Hit a 52 week high of 112.70

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
RCPT 109.24 Receptos Inc $RCPT Hit a 52 week high of 112.70 Currently at 109.24 -1.28 -1.16% With a day low of 108.70 and a total volume of 794,000.

RCPT Receptos Inc Recent Headline News

Receptos to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Thu Nov 06, 3:03PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Credit Suisse Healthcare Conference at The Biltmore Hotel in Phoenix, Arizona. The presentation is scheduled for Wednesday, November 12 at 8:30am. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.24 (-1.28)

Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 109.24 (-1.28)

Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 109.24 (-1.28)

Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.24 (-1.28)

Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.37 (-0.32), WMGI: 27.95 (-0.49), CFN: 57.28 (-0.16), UTHR: 124.21 (-1.12), RCPT: 109.24 (-1.28), WMGIZ: 4.31 (-0.04)

Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 109.24 (-1.28)

Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 50.17 (-0.82), PTLA: 27.39 (-0.33), RCPT: 109.24 (-1.28), IG: 9.45 (-0.25)

Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 26.63 (+0.14), ECHO: 27.33 (-0.21), LAYN: 7.52 (+0.26), NVAX: 4.95 (-0.20), SCYX: 9.00 (+0.10), RCPT: 109.24 (-1.28), TRNX: 25.50 (-0.09), IDTI: 17.73 (-0.07), SANM: 25.60 (-0.23)

Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.39 (-0.14), KSS: 57.22 (+0.41), MU: 33.01 (-0.34), PFE: 29.92 (-0.12), HAL: 53.86 (+0.69), AMGN: 160.25 (-0.10), NQ: 7.18 (+0.20), RGC: 22.15 (-0.07), MS: 35.66 (+0.35), MSG: 75.15 (+0.27), NVAX: 4.95 (-0.20), CQB: 14.43 (+0.01), SRPT: 16.12 (-0.14), RCPT: 109.24 (-1.28), TWTR: 40.31 (-0.53), PTIE: 1.71 (-0.11)

Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 160.25 (-0.10), RCPT: 109.24 (-1.28), NVS: 91.76 (-0.27)

Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 108.20 (-0.81), RCPT: 109.24 (-1.28), ABBV: 61.50 (-1.21)

Stock Futures Positive, Steady; Vasco Rockets, Twitter Fades
at Investor's Business Daily - Tue Oct 28, 8:01AM CDT
Stock futures rolled up moderate gains ahead of Tuesday's open, as investors geared up for a session with many moving parts. Dow futures were steady, trading 73.1 points above fair market value. Nasdaq 100 futures were up a strong 19.4 points, and...
WHR: 175.81 (+0.97), VDSI: 26.63 (+0.14), RCPT: 109.24 (-1.28), BP: 42.06 (+0.19), TWTR: 40.31 (-0.53), AET: 82.29 (-2.41)

RECEPTOS
at Investor's Business Daily - Mon Oct 27, 5:48PM CDT
RECEPTOS (RCPT), a biotech, reported positive phase 2 trial results for its RPC1063 treatment for ulcerative colitis. Shares shot up 25.1% to 85.02.
RCPT: 109.24 (-1.28)

Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
GlobeNewswire - Mon Oct 27, 3:01PM CDT
- Study met primary efficacy and all secondary endpoints with statistical significance for patients on 1 mg dose after 8 weeks of treatment -
RCPT: 109.24 (-1.28)

Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 15.50 (-0.34), ATHL: 58.34 (+0.11), VIPS: 23.34 (-0.04), ARII: 66.28 (+0.15), SBAC: 114.62 (+2.97), BIOF: 7.28 (+0.01), BKW: 32.60 (-0.72), LUV: 38.24 (+0.30), HCA: 65.75 (-3.22), LPDX: 5.23 (+0.01), DTV: 87.40 (-0.08), RCPT: 109.24 (-1.28), WMB: 55.38 (+0.67), BRK.B: 143.61 (+0.32), BRK.A: 214,970.00 (+170.00), SBGL: 7.16 (+0.24), AN: 57.59 (-0.26)

Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
GlobeNewswire - Fri Oct 03, 6:59AM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that the first patient has been treated in a Phase 2 trial of RPC4046, Receptos' development candidate for eosinophilic esophagitis (EoE). RPC4046 is a humanized monoclonal antibody directed against interleukin-13 (IL-13), a target which has been validated in other related allergic indications.
RCPT: 109.24 (-1.28)

The 5 Best Biotech Stocks in 2014...so far
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 26, 7:35AM CDT
Since the quarter is wrapping up and investors are considering their game plan heading into year-end, let's look at biotech's biggest winners for the year, why they've rallied, and whether they make sense for your portfolio . Specifically, let's...
GILD: 106.45 (-0.49), ACHN: 10.11 (-0.15), RCPT: 109.24 (-1.28), PTCT: 40.24 (-1.93), ICPT: 172.59 (-74.39), PBYI: 236.89 (-3.28)

Critical Alerts For FuelCell Energy, Receptos Inc., HD Supply Holdings Inc., Westport Innovations and Organovo Released By InvestorsObserver
PR Newswire - Thu Sep 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FCEL, RCPT, HDS, WPRT and ONVO.
WPRT: 6.06 (+0.38), FCEL: 2.11 (+0.09), ONVO: 6.97 (+0.13), HDS: 29.01 (-0.32), RCPT: 109.24 (-1.28)

Market Maker Surveillance Report. NPSP, CYTK, JDSU, INVT, MNDL, RCPT, Winning Stocks With Lowest Price Friction For Wednesday, September 10th 2014
M2 - Thu Sep 11, 4:12AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4911 companies with "abnormal" market making, 2481 companies with positive Friction Factors and 2383 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NPS Pharmaceuticals Inc (NASDAQ:NPSP), Cytokinetics Inc (NASDAQ:CYTK), JDS UNIPHASE CORPORATION (NASDAQ:JDSU), INVESTAMERICA INC (OTC:INVT), Mandalay Digital Group Inc (OTC:MNDL), (NASDAQ:RCPT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
CYTK: 4.10 (-0.15), INVT: 1.30 (+0.02), RCPT: 109.24 (-1.28), JDSU: 13.63 (+0.21), NPSP: 27.49 (+0.15), MNDL: 3.63 (+0.30)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ATTACK SHARK Partners with Cloud9 League Team

Updated Category News Views 2

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Continue Reading
Nutromics Welcomes Plaxco: Strategic Tech Leap Forward

Updated Category News Views 1

Professor Plaxco’s Dynamic Role at Nutromics Some folks start their day with breakfast and coffee, but Nutromics is grabbing headlines by introducing Professor Kevin Plaxco as the new Chief Scientific Officer. This strategic shift, made public on September 7, 2026, signals Nutromics’ ambition to amplify its DNA-based sensing footprint. As they gear up to launch their...

Continue Reading
Media Forum Spotlights Asia-Pacific Cooperation

Updated Category News Views 3

The Opening Scene: A Gathering with Purpose Well, here we go, diving right into the latest shindig in Shenzhen at the Asia-Pacific Media Forum. Held in China's Guangdong province, they've rounded up over 400 reps from every corner of the globe, all chewing over one key theme: "Building a Path to Shared Prosperity for the Asia-Pacific Community." You could say it's a step...

Continue Reading
Park Systems Expands in the Pacific Northwest

Updated Category News Views 5

Strategic Move into Hillsboro Sparks Industry Buzz Park Systems, already a heavyweight in the nanometrology arena, just made a bold play with the opening of its latest regional office. Nestled in the tech-centric town of Hillsboro, Oregon, this hub is set to redefine how they handle technical support and customer management across the Pacific Northwest. It's like they're...

Continue Reading
Changhong's IFA 2026 Showcase: AI, Culture & Localization

Updated Category News Views 4

Changhong's Game Plan: From Global Reach to Local Touch Well, Changhong's not sitting back at IFA 2026, let me tell you that. This isn't your run-of-the-mill showcase; it's a full-on reveal of what happens when a company takes AI tech and tunes it to the heartbeat of daily life. TVs, fridges, air conditioners—you name it, they've got an AI twist on it. But is this just...

Continue Reading
Clover's RSV Combo Vaccine Shows Promise in Trials

Updated Category News Views 4

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Continue Reading
Pudu D7 Robot Shines at IFA, Setting New Robotics Bar

Updated Category News Views 3

Breaking New Ground in Robotics at IFA Well, here's a nugget for robotics buffs and investors alike: Pudu Robotics, a heavyweight in commercial service robotics, is carving out a fresh chapter with its PUDU D7. Making waves as an honoree at the IFA Innovation Awards, the D7 presents a mash-up of brains and brawn—exemplifying the future path for robotics. The PUDU D7...

Continue Reading
ISO 45010: First Guidance for Menstruation, Menopause

Updated Category News Views 0

Tackling Menstruation and Menopause in the Workplace Today, the International Organization for Standardization (ISO) has taken a bold step forward by launching ISO 45010—a groundbreaking standard aimed at addressing menstruation and menopause in the workplace. Millions endure these natural processes throughout their careers, yet structured policies to support them have...

Continue Reading
Aroa Biosurgery Reports Low Infection Rates: A Milestone

Updated Category News Views 1

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Continue Reading
Rznomics Unveils Breakthrough in Circular RNA Production

Updated Category News Views 0

Decoding the RNA Revolution Ever heard of circular RNA (circRNA)? This ain't your typical strand of genetic code. Unlike their straight-laced, linear counterparts, these RNAs form a loop you can't just break. Picture them as the Kevlar vests of the RNA world—tough, resilient, and packing the promise of next-gen treatments in their covalent loops. Here we’ve got...

Continue Reading

Top 5 Most Recently Viewed Articles

Toll Brothers Reveals Fourth Quarter Success and Growth Strategy

Updated Category News Views 173

Toll Brothers' Impressive Fourth Quarter Results Toll Brothers, Inc. (NYSE: TOL) is proud to announce its financial results for the fourth quarter, showcasing the strength of the luxury home building sector. The company focused on delivering homes that meet the needs of its clients while navigating a challenging economic environment. Quarterly Financial Highlights The...

Continue Reading
Gevo Expands Sustainable Energy Portfolio with New Acquisition

Updated Category News Views 171

Gevo Advances Its Renewable Energy Strategy Gevo, Inc. (NASDAQ: GEVO), a leading innovator in the production of sustainable hydrocarbon fuels and chemicals, has recently acquired the assets of Red Trail Energy. This includes an ethanol production facility and carbon capture and sequestration (CCS) technologies, marking a significant milestone in Gevo's strategic...

Continue Reading
Swipesum and Facility Ally Transform Eating and Sports Payments

Updated Category News Views 156

Revolutionizing Payment Solutions in the Event Space ST. LOUIS -- In an exciting move for the world of payment processing, Swipesum, a frontrunner in merchant services consultancy, has announced a strategic partnership with Facility Ally, a notable provider of business solutions tailored for sports and entertainment venues. Their collaborative endeavor is set to redefine...

Continue Reading
Investors Unite: Join the PACS Lawsuit for Justice

Updated Category News Views 140

PACS Group, Inc. Investors Encouraged to Act Attorney Advertising -- A significant opportunity has arisen for investors of PACS Group, Inc. to stand up for their rights in a class action lawsuit. The law firm Bronstein, Gewirtz & Grossman, LLC has filed this crucial case against PACS Group and a number of its officers, aiming to address substantial losses incurred by...

Continue Reading
US Equities Preparing for a Strong Finish Amid Positive Trends

Updated Category News Views 104

Market Trends Shaping US Equities As we near the end of the second quarter earnings season, the reports from S&P 500 companies have been heartening. The overall earnings-per-share growth is currently at 11.8% year-over-year, reflecting a vigorous economic backdrop. Such growth indicates that many businesses are thriving, continuing a trend that saw 81% of the companies...

Continue Reading